Can a heart drug shield kidneys during bypass surgery?

NCT ID NCT07617675

Not yet recruiting Prevention Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a drug called recombinant human brain natriuretic peptide (rhBNP), given continuously during and after heart surgery, can prevent acute kidney injury. It includes 694 high-risk adults undergoing elective heart surgery with a heart-lung machine. Participants receive either the drug or a placebo for about 48 hours, and researchers track kidney function for a week.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: recombinant human brain natriuretic peptide (rhBNP)
What this could lead to: If it works, this could provide a way to prevent kidney damage during heart surgery, reducing hospital stays and improving recovery.
What could go wrong: This is a Phase 4 trial, but results are not yet available. The drug may not prevent kidney injury as hoped, and side effects like low blood pressure are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AKI - ACUTE KIDNEY INJURY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AKI - ACUTE KIDNEY INJURY CARDIAC SURGICAL PROCEDURES CARDIOPULMONARY BYPASS

Contacts and locations

Locations

Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.